Table 2.
Efficacy assessment of IFX or AZA monotherapy in maintaining therapy of Crohn's disease, n (%).
| Efficacy assessment | IFX monotherapy group (N = 22) | IFX-AZA sequential therapy group (N = 57) | All (N = 79) | P value |
|---|---|---|---|---|
| Deep remission at week 84 | 18 (81.8) | 26 (45.6) | 44 (55.7) | 0.004 |
| Deep remission at week 138 | 17 (77.3) | 21 (36.8) | 38 (48.1) | 0.001 |
| Clinical remission at week 57 | 21 (95.5) | 52 (91.2) | 73 (92.4) | 0.871 |
| Clinical remission at week 84 | 20 (90.9) | 49 (86.0) | 69 (87.3) | 0.830 |
| Clinical remission at week 111 | 19 (86.4) | 48 (84.2) | 67 (84.8) | 0.999 |
| Clinical remission at week 138 | 19 (86.4) | 45 (78.9) | 64 (81.0) | 0.665 |
| Complete endoscopic remission at week 84 | 18 (81.8) | 27 (47.4) | 45 (57.0) | 0.012 |
| Complete endoscopic remission at week 138 | 17 (77.3) | 22 (38.6) | 39 (49.4) | 0.002 |
| Endoscopic remission at week 84 | 21 (95.5) | 47 (82.5) | 68 (86.1) | 0.257 |
| Endoscopic remission at week 138 | 19 (86.4) | 45 (78.9) | 64 (81.0) | 0.665 |
| Endoscopic improvement at week 84 | 21 (95.5) | 53 (93.0) | 74 (93.7) | 0.999 |
| Endoscopic improvement at week 138 | 20 (90.9) | 52 (91.2) | 72 (91.1) | 0.999 |